Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGS) EBIT Margin: 2020-2025

Historic EBIT Margin for GeneDx Holdings (WGS) over the last 6 years, with Sep 2025 value amounting to -2.78%.

  • GeneDx Holdings' EBIT Margin rose 734.00% to -2.78% in Q3 2025 from the same period last year, while for Sep 2025 it was 2.48%, marking a year-over-year increase of 2406.00%. This contributed to the annual value of -7.60% for FY2024, which is 8155.00% up from last year.
  • Latest data reveals that GeneDx Holdings reported EBIT Margin of -2.78% as of Q3 2025, which was down 131.92% from 8.73% recorded in Q2 2025.
  • GeneDx Holdings' EBIT Margin's 5-year high stood at 9.21% during Q4 2024, with a 5-year trough of -529.56% in Q4 2022.
  • Its 3-year average for EBIT Margin is -37.12%, with a median of -15.00% in 2024.
  • As far as peak fluctuations go, GeneDx Holdings' EBIT Margin slumped by 35,302bps in 2022, and later spiked by 48,489bps in 2023.
  • Quarterly analysis of 5 years shows GeneDx Holdings' EBIT Margin stood at -200.31% in 2021, then tumbled by 32,925bps to -529.56% in 2022, then spiked by 48,489bps to -44.66% in 2023, then surged by 5,387bps to 9.21% in 2024, then spiked by 734bps to -2.78% in 2025.
  • Its EBIT Margin stands at -2.78% for Q3 2025, versus 8.73% for Q2 2025 and -5.22% for Q1 2025.